Search Results 2381-2390 of 18196 for rheumatoid arthritis

  1. Overview - Tendon and Soft Tissue Biology: Peter C. Amadio - Mayo Clinic Research

    Appropriate surgical repair and reconstruction techniques. Role of growth factor on tendon healing and adhesion formation. Research in our lab encompasses a ...

  2. Phase I Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis due to Traumatic Spinal Cord Injury

    Taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within 3 months prior to study enrollment. Ongoing infectious ...

  3. Pentoxifylline Treatment in Acute Pancreatitis (AP) - Mayo Clinic

    The objective of our research is to determine whether inhibition of the tumor necrosis factor ... The levels of markers of inflammation of C-reactive protein (C- ...

  4. Technical Reports - Department of Quantitative Health Sciences - Mayo Clinic Research

    Population attributable risk (PAR) is a function of time because both the prevalence of a risk factor and its effect on exposed individuals may change over ...

  5. Publications - Mike M. Bierle, M.D. - Mayo Clinic

    Littrell LA, Leslie DF, Bierle DM, Wenger DE. Progressive Monoarticular Inflammatory Arthritis Following Influenza Vaccination. Mayo Clin Proc Innov Qual ...

  6. Bone cancer - Doctors and departments - Mayo Clinic

    ... arthritis, Knee arthritis, Soft tissue sarcoma, Sarcoma, Bone metastasis, Failed total hip replacement, Failed total knee replacement, Pelvic bone tumor ...

  7. Bone cancer - Doctors and departments - Mayo Clinic

    ... arthritis, Knee arthritis, Soft tissue sarcoma, Sarcoma, Bone metastasis, Failed total hip replacement, Failed total knee replacement, Pelvic bone tumor ...

  8. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined Regimen Of Mosunetuzumab And Venetoclax In Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia - Mayo Clinic

    ... factor agents) within 2 weeks prior to the first dose of study treatment; any other anti-cancer therapy, whether investigational or approved, including but ...

  9. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy - Mayo Clinic

    ... factor (TNF) therapy. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

  10. Publications - Fernando A. Rivera, M.D. - Mayo Clinic

    Depression: A Modifiable Risk Factor for Poor Outcomes in Fibromyalgia. J Prim Care Community Health. 2022 Jan-Dec; 13:21501319221120738. View PubMed; Bruce ...